Articles dans des revues avec comité de lecture (396)
  1. 109. Agarwal, N., Hwang, A., Mosher, R., Wasserman, E., Wu, G., Zhang, H., Zieba, R., Elmeliegy, M., Machiels, J. P., Suárez, C., Lewis, N., Higgins, M., Wisinski, K., Awada, A., Maur, M., & Steiner, M. (2016). Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer. The oncologist, 21(5), 535-536. doi:10.1634/theoncologist.2015-0502
  2. 110. Gebhart, G., Tol, J., Oyen, W. J. G., Vugts, D., Hoekstra, O. O., Schröder, C. P., Menke-van der Houven van Oordt, C. W., Guiot, T., Brouwers, A. A., Awada, A., de Vries, E. G. E. L. E., Lamberts, L. L., Flamen, P., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M. T., & Aftimos, P. (2016). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Annals of oncology, 27(4), mdv577, 619-624. doi:10.1093/annonc/mdv577
  3. 111. Lalami, Y., Garcia, C., Flamen, P., Ameye, L., Paesmans, M., & Awada, A. (2016). Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Head & neck, 38(3), 347-354. doi:10.1002/hed.23898
  4. 112. Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Sales, F., van Kempen, L., Sibille, C., Awada, A., Marine, J.-C., & Ghanem, G. E. (2016). P53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. European journal of cancer, 55, 98-110. doi:10.1016/j.ejca.2015.12.002
  5. 113. Kourie Hampig, R., Awada, G., & Awada, A. (2016). Unknown primary tumors: Is there a future therapeutic role for immune checkpoint inhibitors? Future oncology, 12(4), 429-431. doi:10.2217/fon.15.329
  6. 114. Schöffski, P., Aftimos, P., Dumez, H., Deleporte, A., De Block, K., Costermans, J., Billiet, M., Meeus, M. A., Lee, C., Schnell, D., Goeldner, R. G., & Awada, A. (2016). A phase i study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 77(1), 99-108. doi:10.1007/s00280-015-2914-5
  7. 115. Lalami, Y., & Awada, A. (2016). Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer treatment reviews, 43, 113-123. doi:10.1016/j.ctrv.2016.01.001
  8. 116. Awada, G., Gombos, A., Aftimos, P., & Awada, A. (2016). Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. Expert opinion on emerging drugs, 21(1), 91-101. doi:10.1517/14728214.2016.1146680
  9. 117. Limentani, S. S., Disis, M., Awada, A., Berlière, M., Amant, F., Levine, E., Burny, W., Callegaro, A., De Sousa Alves, P. M., Louahed, J., Brichard, V., Csampone, M., Lehmann, F., Dorval, T., Curigliano, G., de Boer, R., Vogel, C., White, S., Bachelot, T., & Canon, J.-L. (2016). A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast cancer research and treatment, 156(2), 319-330. doi:10.1007/s10549-016-3751-x
  10. 118. Awada, A., Penel, N., & Kotecki, N. (2016). Eribulin in the soft tissue sarcoma therapeutic landscape: Little is good, then more is better. Translational lung cancer research, 5, S1160-S1162. doi:10.21037/tcr.2016.11.54
  11. 119. Cortes, J., Velikova, G., Hudgens, S., Twelves, C., Perez, E. A., Awada, A., Yelle, L., McCutcheon, S., Kaufman, P. P., & Forsythe, A. (2015). Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154(3), 509-520. doi:10.1007/s10549-015-3633-7
  12. 120. Twelves, C., Jove, M., Perez, E. A., Cortes, J., Kaufman, P. P., Yelle, L., Awada, A., Binder, T. T., Olivo, M., Song, J., & O'Shaughnessy, J. (2015). "New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast cancer research, 17(1), 150. doi:10.1186/s13058-015-0657-1
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>